Drug General Information
Drug ID	D0F3OM
Former ID	DNC006931
Drug Name	2-((3,5-diamino-1H-pyrazol-4-yl)diazenyl)phenol
Drug Type	Small molecular drug
Indication	Discovery agent		Investigative	[528490]
Structure		Download 2D MOL 3D MOL
Formula	C9H10N6O
Canonical SMILES	C1=CC(=NNC2=C(NN=C2N)N)C(=O)C=C1
InChI	1S/C9H10N6O/c10-8-7(9(11)15-14-8)13-12-5-3-1-2-4-6(5)16/h1-4,13H,(H5,10,11,14,15)/b12-5+
InChIKey	UJKRKBDYVKFKKQ-LFYBBSHMSA-N
PubChem Compound ID	44417638
Target and Pathway
Target(s)	G1/S-specific cyclin E1	Target Info	Inhibitor	[528490]
	Cell division protein kinase 2	Target Info	Inhibitor	[528490]
KEGG Pathway	Cell cycle
	Oocyte meiosis
	p53 signaling pathway
	PI3K-Akt signaling pathway
	Hepatitis B
	Measles
	Pathways in cancer
	Viral carcinogenesis
	MicroRNAs in cancer
	Prostate cancer
	Small cell lung cancerhsa04068:FoxO signaling pathway
	Progesterone-mediated oocyte maturation
	Herpes simplex infection
	Epstein-Barr virus infection
	Small cell lung cancer
NetPath Pathway	IL2 Signaling Pathway
	TCR Signaling PathwayNetPath_11:TCR Signaling Pathway
PANTHER Pathway	Cell cycle
	Parkinson disease
	p53 pathway
	p53 pathway feedback loops 2P00059:p53 pathway
	p53 pathway feedback loops 2
Pathway Interaction Database	Signaling events mediated by PRL
	E2F transcription factor network
	mTOR signaling pathway
	FOXM1 transcription factor network
	BARD1 signaling events
	PLK3 signaling events
	Regulation of retinoblastoma proteinsmad2_3nuclearpathway:Regulation of nuclear SMAD2/3 signaling
	p73 transcription factor network
	ATR signaling pathway
	IL2-mediated signaling events
	FoxO family signaling
	p53 pathway
	Regulation of retinoblastoma protein
Reactome	E2F mediated regulation of DNA replication
	G0 and Early G1
	SCF(Skp2)-mediated degradation of p27/p21
	DNA Damage/Telomere Stress Induced Senescence
	Cyclin E associated events during G1/S transition
	G1/S-Specific Transcription
	p53-Dependent G1 DNA Damage ResponseR-HSA-1538133:G0 and Early G1
	Activation of ATR in response to replication stress
	Regulation of APC/C activators between G1/S and early anaphase
	Senescence-Associated Secretory Phenotype (SASP)
	Processing of DNA double-strand break ends
	G2 Phase
	Orc1 removal from chromatin
	Cyclin A/B1 associated events during G2/M transition
	p53-Dependent G1 DNA Damage Response
	Cyclin A:Cdk2-associated events at S phase entry
	Meiotic recombination
	Factors involved in megakaryocyte development and platelet production
WikiPathways	DNA Damage Response
	ID signaling pathway
	G1 to S cell cycle control
	Retinoblastoma (RB) in Cancer
	Integrated Pancreatic Cancer Pathway
	Parkinsons Disease Pathway
	Parkin-Ubiquitin Proteasomal System pathway
	Signaling Pathways in Glioblastoma
	TSH signaling pathway
	Mitotic G1-G1/S phases
	Cell Cycle
	miRNAs involved in DNA damage response
	miRNA Regulation of DNA Damage Response
	Androgen receptor signaling pathwayWP707:DNA Damage Response
	DNA Replication
	M/G1 Transition
	S Phase
	Meiotic Recombination
	Aryl Hydrocarbon Receptor
	ATM Signaling Pathway
	Spinal Cord Injury
	Oncostatin M Signaling Pathway
	Prostate Cancer
	Integrated Breast Cancer Pathway
	Integrated Cancer pathway
	Synthesis of DNA
	Regulation of DNA replication
	Mitotic G2-G2/M phases
	Factors involved in megakaryocyte development and platelet production
	APC/C-mediated degradation of cell cycle proteins
	Cell Cycle Checkpoints
References
Ref 528490	J Med Chem. 2006 Nov 2;49(22):6500-9.4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
Ref 528490	J Med Chem. 2006 Nov 2;49(22):6500-9.4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.